Marianne De Backer, Vir Biotechnology CEO
June 5, 2024 05:57 AM EDTUpdated 09:48 AM
R&D

Vir's ear­ly Phase 2 he­pati­tis D da­ta show re­duc­tion, re­moval of virus with com­bo and monother­a­py

Katherine Lewin

News Reporter

Vir’s chron­ic he­pati­tis D treat­ment re­duced the pres­ence of the virus RNA as well as nor­mal­ized cer­tain liv­er en­zyme lev­els across 24 weeks in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times